Stent thrombosis with drug-eluting stents: is the paradigm shifting?
發布時(shí)間(jiān)：
2016-08-12 09:20
來(lái)源：
First-generation drug-eluting stents (DES), which impart the controlled release of sirolimus or paclitaxel from durable polymers to the vessel wall, have been consistently shown to reduce the risk of restenosis and target vessel revascularization compared with bare metal stents (BMS). However, stent thrombosis (ST) emerged as a major safety concern with first-generation DES early after their adoption in clinical practice, requiring prolonged dual antiplatelet therapy. Pathological studies have shown that first-generation DES are associated with delayed arterial healing and polymer hypersensitivity reactions resulting in chronic inflammation, predisposing to late and very late ST. Second-generation DES have been developed to overcome these issues with improved stent designs and construction and the use of biocompatible and bioabsorbable polymers. Meta-analyses have shown that the thin-strut, fluoropolymer-coated cobalt-chromium everolimus-eluting stent (CoCr-EES) may be associated with lower rates of definite ST than other DES and, unexpectedly, even lower than BMS. The thin-strut structure of the stent platform, the thromboresistant properties of the fluoropolymer, and the reduced polymer and drug load may contribute to the low rate of ST with CoCr-EES. The notion of DES being safer than BMS represents a paradigm shift in the evolution of percutaneous coronary intervention. The relative safety and efficacy of fluoropolymer-coated CoCr-EES, DES with bioabsorbable polymers, and fully bioresorbable scaffolds are the subject of numerous ongoing large-scale trials.
公司信息
北京飛渡醫療器械有限公司
Beijing Advanced Medical Technologies,Ltd.Inc.
聯系我們
地址：北京市大(dà)興區(qū)永旺西路26号院中關村醫(yī)療器(qì)械園11号樓
電(diàn)話(huà)：010-6297-7955 郵箱：amt@ametcorp.com
微信聯系
@Copyright 2022 北京飛渡醫療器械有限公司 All rights reserved 版權所有(yǒu)
京ICP備11028039号 網站(zhàn)建設：中企動力 南京